Stockscreener 앱 받기
2.08
0.48%
0.01
시장 영업 전:
2.07
-0.01
-0.48%
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
CMPX|Compass Therapeutics Inc.|Price:2.092|Chg%:+0.022 - TradingKey
Compass Therapeutics, Inc. Revenue Breakdown – NASDAQ:CMPX - TradingView
Compass Therapeutics Inc. (CMPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Compass Therapeutics to present Phase 2/3 tovec... - Pluang
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - The Manila Times
Compass Therapeutics’ COMPANION-002 Biliary Tract Cancer Study Accepted for Oral Presentation at ESMO 2026 - Quiver Quantitative
Compass Therapeutics Inc. (CMPX) Institutional Confidence - TradingKey
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity - Seeking Alpha
Compass Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesInvestor Earnings Call - DonanımHaber
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Clinical-Stage Focus - dars.gov.et
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Driven by Disciplined SpendingHigh Estimate Range - dars.gov.et
Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
If You Invested $1,000 in Compass Therapeutics Inc (CMPX) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX) - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
Compass Showcases Promising Tovecimig Data, Eyes Commercialization - TipRanks
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement - TradingView
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic - The National Law Review
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to earnings forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
$Compass Therapeutics (CMPX.US)$ - Moomoo
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings - Moomoo
Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX) - TradingView
CMPX Forecast — Price Target — Prediction for 2027 - TradingView
Compass Therapeutics (CMPX) News Flow - Moomoo
Compass Therapeutics Adopts Second Amended and Restated Bylaws - The Globe and Mail
Compass Therapeutics Q1 2026 Earnings: Narrow EPS Beat Amid No Revenue; Stock Declines SlightlyAdjusted Earnings Analysis - dars.gov.et
Compass Therapeutics Inc. (CMPX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing - Insider Monkey
5 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
1.97%
0.83%
자본화:
|
볼륨(24시간):